{"id":"0f61dfc2a208","type":"article","url":"https://hartvaat.nl/2022/11/29/favor-iii-qfr-geleide-pci-verbetert-tweejaarsuitkomsten/","title":"FAVOR III: QFR-geleide PCI verbetert tweejaarsuitkomsten","title_en":"2-Year Outcomes of Angiographic Quantitative Flow Ratio-Guided Coronary Interventions.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.09.007","source_url":"https://doi.org/10.1016/j.jacc.2022.09.007","authors":["Lei Song","Bo Xu","Shengxian Tu","Changdong Guan","Zening Jin","Bo Yu","Guosheng Fu","Yujie Zhou","Jian'an Wang","Yundai Chen","Jun Pu","Lianglong Chen","Xinkai Qu","Junqing Yang","Xuebo Liu","Lijun Guo","Chengxing Shen","Yaojun Zhang","Qi Zhang","Hongwei Pan","Rui Zhang","Jian Liu","Yanyan Zhao","Yang Wang","Kefei Dou","Ajay J Kirtane","Yongjian Wu","William Wijns","Weixian Yang","Martin B Leon","Shubin Qiao","Gregg W Stone"],"significance":7,"published":"2022-11-29","source_date":"2022-11-29","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/fractional-flow-reserve/","https://hartvaat.nl/kennis/diagnostiek/cardiale-mri/"],"congress":"","summary_en":"Two-year FAVOR III results confirmed that angiographic QFR-guided PCI maintains superior outcomes compared with conventional angiography guidance, supporting the durability of wire-free physiological assessment for coronary intervention decisions.","created":"2026-07-03T10:30:05Z","updated":"2026-07-03T13:29:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Tweejaarsresultaten van FAVOR III bevestigden dat angiografie-gebaseerde quantitative flow ratio (QFR)-geleide PCI de klinische uitkomsten verbeterde vergeleken met conventionele angiografie-geleide PCI. QFR biedt een draadloze functionele beoordeling die de besluitvorming verbetert.","abstract_original":"BACKGROUND: In the multicenter, randomized, sham-controlled FAVOR (Comparison of Quantitative Flow Ratio Guided and Angiography Guided Percutaneous Intervention in Patients with Coronary Artery Disease) III China trial, quantitative flow ratio (QFR)-based lesion selection improved 1-year clinical outcomes compared with conventional angiographic guidance for percutaneous coronary intervention (PCI). OBJECTIVES: The purpose of this study was to determine whether the benefits of QFR guidance persist at 2 years, particularly for patients in whom QFR changed the revascularization strategy. METHODS: Eligible patients were randomized to a QFR-guided strategy (PCI performed only if QFR ≤0.80) or a standard angiography-guided strategy. Major adverse cardiac events (MACE), a composite of all-cause death, myocardial infarction (MI), or ischemia-driven revascularization occurring within 2 years were analyzed in the intention-to-treat population. RESULTS: Among 3,825 randomized participants, 2-year MACE occurred in 161 of 1,913 (8.5%) patients in the QFR-guided group and in 237 of 1,912 (12.5%) patients in the angiography-guided group (HR: 0.66; 95% CI: 0.54-0.81; P < 0.0001), driven by fewer MIs (4.0% vs 6.8%; HR: 0.58; 95% CI: 0.44-0.77; P = 0.0002) and ischemia-driven revascularizations (4.2% vs 5.8%; HR: 0.71; 95% CI: 0.53-0.95; P = 0.02) in the QFR-guided group. Landmark analysis showed consistent results within the first year and between 1-2 years (Pint = 0.99). Although the 2-year MACE rate was lower in the QFR-guided group in both patients with and without revascularization strategy changes, the extent of outcome improvement was greater (Pint = 0.009) among those patients in whom the preplanned PCI strategy was modified by QFR. CONCLUSIONS: QFR-guided lesion selection improved 2-year clinical outcomes compared with standard angiography guidance. The benefits were most pronounced among patients in whom QFR assessment altered the planned revascularization strategy. (FAVOR III China Study [The Comparison of Quantitative Flow Ratio Guided and Angiography Guided Percutaneous Intervention in Patients with Coronary Artery Disease] NCT03656848)."}